Bitopertin

比托哌汀

Report date: 2026/04/14 20:00:15
NME

Base Information

Drug NameBitopertin
Drug Alias NameBitopertinum贝托氟汀PaliflutineBitopertinaBitopertine +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlycine transporter 1 inhibitors
TargetsGlycine transporter 1
Therapy Area/IndicationsX-linked ProtoporphyriaSchizophreniaObsessive-Compulsive Disorder +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[38] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesF. Hoffmann-La Roche LtdNational Heart, Lung, And Blood Institute (Nhlbi)Disc Medicine Inc +[4] 
Inactive CompaniesWake Forest University Health Sciences
Active IndicationsX-linked ProtoporphyriaSchizophreniaAnemia, Diamond-Blackfan +[4] 
Inactive IndicationsObsessive-Compulsive DisorderPorphyriasbeta-Thalassemia

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG